Becotatug (JMT-101) is an IgG1 antibody targeting EGFR that can also be conjugated to Afatinib and Osimertinib as a synthetic ADC.
References:
[1]. Brazel D, Kroening G, Nagasaka M. Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options. BioDrugs. 2022 Nov;36(6):717-729.